This study aims to learn how to best optimize a mobile iPhone Cognitive Behavioral Therapy (CBT) app, and whether a personalized mobile iPhone CBT program is more effective than a more comprehensive general mobile iPhone CBT program. Although the app is new, it is based on Cognitive Behavior Therapy, which is a traditional “gold-standard” behavior therapy approach to treat anxiety disorders.

This clinical trial is for men and women who have advanced cancer that may have spread locally or to other parts of the body and is known to have a mutation in a member of the RAS gene family. RAS genes make proteins inside cells that control cell growth and cell survival, and cancers with a mutated RAS gene often grow and spread more quickly and are harder to treat.
   

The purpose of this study is to test the safety of the study drug, AAVrh.10hFXN, which is an adeno-associated virus serotype rh10 gene transfer vector and see what effects it has to treat the cardiomyopathy associated with Friedreich’s ataxia (FA). The study also aims to find the highest dose of the study drug that can be given without causing severe side effects.

AAVrh.10hFXN is considered experimental, which means it has not yet been approved by the U.S. Food and Drug Administration (FDA).

This study is for men and women who have been diagnosed with liver cirrhosis due to Nonalcoholic Steatohepatitis (NASH). This study will test the following experimental/investigational drugs: an injectable named semaglutide and a fixed-dose combination tablet named cilofexor/firsocostat (CILO/FIR) for NASH. 

This clinical trial is for men and women with acute myeloid leukemia (AML) whose cancer has been treated before and has either recurred or did not respond to prior therapy.   

This is one of the first-in-human studies to try to understand how an investigational drug called BP1002 works in the human body and if BP1002 could help cancer patients in the future. Investigational means that BP1002 has not yet been approved by the U.S. Food and Drug Administration (FDA).

Cancers behave differently in different patients; thus, not all therapies will work for everyone. By identifying biological pathways and specific genetic alterations in different cancers, patient treatments can be better tailored, resulting in a personalized approach to treatment.

The purpose of this study is to assess serum testosterone levels after administration of clomiphene citrate (CC) in men with low serum testosterone.

Clomiphene citrate is approved by the U.S. Food and Drug Administration (FDA) to treat some types of infertility in women and is sometimes prescribed off-label for treatment of low testosterone in men. Clomiphene citrate is not FDA approved for this purpose.

This study will test the effect of the oral medication, escitalopram, on male fertility in comparison to a placebo (pills with no study drug). Escitalopram is approved by the U.S. Food and Drug Administration (FDA) and is a commonly prescribed anti-depressant among men of reproductive age. Escitalopram is thought to have negative effects on male fertility but has never been assessed in comparison to a placebo or for healthy individuals.